Loading…
Loading…
RFCS (Refocus Group, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
RFCS does not currently pay a dividend.
See exactly how RFCS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RFCS and 80,000+ other tickers.
Refocus Group, Inc. is a medical technology firm dedicated to the research and creation of therapies for various human vision conditions, particularly presbyopia. A key offering is the VisAbility Micro-Insert System, an experimental medical device currently undergoing clinical evaluations for its application in treating presbyopia affecting both eyes. The organization caters to the needs of both patients and ophthalmic professionals. Founded in 1994, this company operates from its base in Dallas, Texas.
Teladoc Health Inc. (NYSE:TDOC) shares are trending Wednesday as investors take a fresh look at the company.
SINGAPORE, June 24, 2026 (GLOBE NEWSWIRE) -- Currenc Group Inc. (Nasdaq: CURR) (“Currenc” or the “Company”), a leading AI-powered fintech provider serving financial institutions globally, today announced a targeted operational restructuring for its indirect Indonesian digital payments subsidiary PT Walletku Indompet Indonesia (“WalletKu”), aligned with the Group's long-term strategy to prioritize high-margin artificial intelligence and Web3 verticals and unlock sustainable shareholder value.
The AI company will combine ChatGPT, Codex app and browser in an effort to focus and streamline its resources.
GN Store Nord A/S (GNNDY) Discusses Sale of Hearing Business to Amplifon and Strategic Refocus on Technology Innovation Transcript
Deutsche Bank is upgraded to a buy, driven by positive macro forecasts and strong organic growth in loans and net asset inflows. DB benefits from sector tailwinds, improved operational efficiency, and a solid credit rating, despite lagging peers in profit margin and return on equity. Valuation remains below peers, reflecting justified caution due to DB's lower profitability and significant office CRE exposure; price forecast implies only 2% upside.